Recombinant Zebrafish ARHGEF1A

• Cat.No.: ARHGEF1A-5196Z
• Product Overview: Recombinant Zebrafish ARHGEF1A full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: arhgef1a Rho guanine nucleotide exchange factor (GEF) 1a [ Danio rerio (zebrafish) ]
• Official Symbol: ARHGEF1A
• Gene ID: 368266
• mRNA Refseq: NM_001081631
• Protein Refseq: NP_001075100
• UniProt ID: A2RUX1

Reviews

11/25/2022

This can help ensure compatibility between different components used in the trials and ease the overall experimental workflow.

10/19/2022

Their technical expertise and prompt customer service have been instrumental in resolving any challenges or questions I encountered throughout my research journey.

09/20/2022

A manufacturer that can deliver the protein promptly and reliably can save researchers time and allow them to proceed with their experiments without unnecessary delays.

06/06/2021

In addition to its scientific advantages, the manufacturer of the ARHGEF1A protein stands out for their exceptional support and assistance.

08/09/2019

Its ability to modulate the activity of essential signaling pathways involved in these processes makes it a valuable tool for unraveling their complexities.

07/18/2019

A reliable manufacturer should be able to provide a consistently pure and high-quality ARHGEF1A protein, ensuring that the samples are suitable for research purposes.

03/05/2019

the manufacturer's commitment to innovation and product development instills confidence in the reliability and future potential of the ARHGEF1A protein.

07/10/2016

A manufacturer that offers customization options can enable the researcher to adhere to their experimental design requirements more effectively.

Q&As

Are there any known animal models with ARHGEF1A mutations or knockouts?

Currently, there is limited information available on animal models specifically with ARHGEF1A mutations or knockouts. However, studies have utilized RNA interference techniques or gene knockout approaches to investigate the function of ARHGEF1A in cellular processes and disease contexts. These studies have provided insights into the role of ARHGEF1A, particularly in cancer cell migration and invasion.

Does ARHGEF1A have any isoforms?

Yes, alternative splicing of the ARHGEF1A gene can generate multiple isoforms of the protein. These isoforms may differ in their structural domains or regulatory regions, leading to functional diversity or differential regulation of ARHGEF1A activity. However, the specific functions of individual ARHGEF1A isoforms are still being characterized.

Is ARHGEF1A expression regulated in response to extracellular signals?

Yes, the expression and activity of ARHGEF1A can be regulated by various extracellular signals and signaling pathways. For example, ARHGEF1A expression has been found to be induced by certain growth factors, such as epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), in different cell types.

Can ARHGEF1A function as a signaling hub or scaffold protein?

Yes, ARHGEF1A has been proposed to function as a signaling hub or scaffold protein due to its ability to interact with multiple proteins and coordinate signaling events. By binding to Rho GTPases and other signaling molecules, ARHGEF1A can bring them into proximity and facilitate their signaling interactions. This scaffolding function allows ARHGEF1A to regulate signal transduction pathways and coordinate cellular responses.

Are there any therapeutic implications related to ARHGEF1A?

The involvement of ARHGEF1A in cancer progression and metastasis suggests that it could be a potential therapeutic target. Modulating the activity or expression of ARHGEF1A may help to inhibit cancer cell migration and invasion. However, further research is needed to elucidate the exact mechanisms and potential therapeutic strategies related to ARHGEF1A. Additionally, since ARHGEF1A is involved in various cellular processes beyond cancer, it may have implications in other diseases as well, warranting further investigation.

Is there any evidence of ARHGEF1A involvement in cancer?

Yes, there is evidence suggesting that ARHGEF1A may play a role in cancer progression and metastasis. Studies have shown that ARHGEF1A is overexpressed in certain types of cancer, including breast and lung cancer, and its expression levels correlate with tumor aggressiveness and poor patient prognosis. Additionally, ARHGEF1A has been implicated in promoting cancer cell migration, invasion, and metastasis through its regulation of Rho GTPases and actin cytoskeleton dynamics. However, more research is needed to fully understand the mechanisms and implications of ARHGEF1A in cancer.

Are there any known interacting proteins of ARHGEF1A?

ARHGEF1A has been reported to interact with several proteins involved in signaling pathways and cytoskeletal dynamics. For example, it can interact with Rho GTPases, such as RhoA, Rac1, and Cdc42, to activate them. ARHGEF1A may also interact with other signaling molecules or adaptor proteins to modulate its activity and downstream signaling. However, the full repertoire of ARHGEF1A interacting proteins is not yet completely characterized and further studies are required to elucidate its complete interactome.

Are there any known post-translational modifications of ARHGEF1A?

Yes, ARHGEF1A can undergo post-translational modifications, including phosphorylation and ubiquitination. Phosphorylation of specific residues in ARHGEF1A can regulate its activity and protein-protein interactions, modulating its function in cellular processes. Ubiquitination, on the other hand, can target ARHGEF1A for degradation or affect its subcellular localization.

Can mutations in the ARHGEF1A gene lead to disease?

Currently, there is limited information on disease-related mutations in the ARHGEF1A gene. However, some studies have reported alterations in ARHGEF1A expression or activity in certain diseases. For instance, dysregulation of ARHGEF1A has been implicated in cancer progression and metastasis in specific contexts. Further research is needed to determine the extent of ARHGEF1A's involvement in diseases and the potential impact of genetic mutations on its function.

Is ARHGEF1A involved in any specific cellular processes or signaling pathways?

Yes, ARHGEF1A is known to play a role in various cellular processes and signaling pathways. It is involved in the regulation of cytoskeletal dynamics, cell migration, cell adhesion, and cell proliferation. ARHGEF1A-mediated activation of Rho GTPases can impact actin filament organization, cell shape changes, and signal transduction cascades. Additionally, ARHGEF1A seems to be implicated in some signaling pathways associated with cancer progression and metastasis, but its precise involvement may vary depending on the cellular context.

Are there any known diseases or disorders associated with ARHGEF1A?

Currently, there are no specific diseases or disorders that have been directly linked to ARHGEF1A mutations or dysregulation. However, ARHGEF1A's involvement in cellular processes and signaling pathways suggests it may play a role in various disease contexts, including cancer progression and metastasis. Further research is needed to fully understand the implications of ARHGEF1A in disease pathogenesis.

Can ARHGEF1A be regulated by small molecule inhibitors or activators?

While there is currently limited information on small molecule inhibitors or activators specific to ARHGEF1A, the activity of Rho GTPases, which are activated by ARHGEF1A, can be modulated by small molecules targeting their signaling pathways. These molecules can either inhibit Rho GTPase activation indirectly by targeting upstream regulators or directly interact with Rho GTPases themselves. Further research is needed to identify specific small molecules that can directly regulate ARHGEF1A activity.

Is there any research suggesting a potential therapeutic target in ARHGEF1A?

While ARHGEF1A itself is not currently considered a direct therapeutic target, its involvement in signaling pathways and cellular processes related to diseases like cancer makes it an intriguing molecule for further investigation. By understanding the precise mechanisms and downstream effects of ARHGEF1A, it may be possible to identify potential therapeutic targets or develop strategies to modulate its activity indirectly for therapeutic purposes. However, additional research is needed to determine the full therapeutic potential of ARHGEF1A in various disease contexts.

Has ARHGEF1A been implicated in any developmental processes?

While not extensively studied, there is some evidence suggesting that ARHGEF1A may have a role in developmental processes. Studies in zebrafish have shown that ARHGEF1A is involved in neuronal development, particularly in axon guidance and formation of neural circuits. However, more research is needed to fully understand the extent of ARHGEF1A's involvement in developmental processes across different organisms and tissues.

Is ARHGEF1A highly conserved across species?

ARHGEF1A shows a high degree of conservation across species. Homologs of ARHGEF1A can be found in various organisms, including mammals, birds, reptiles, amphibians, and fish. This high conservation suggests that ARHGEF1A plays an important role in fundamental cellular processes that are conserved throughout evolution.

Are there any known interactions between ARHGEF1A and other proteins?

Yes, ARHGEF1A can interact with multiple proteins to regulate various cellular processes. It directly interacts with Rho GTPases, such as RhoA, Rac1, and Cdc42, to activate them and initiate downstream signaling cascades. ARHGEF1A can also interact with other proteins involved in cytoskeletal dynamics, cell migration, and adhesion, such as actin-binding proteins and integrins. Additionally, ARHGEF1A may interact with signaling molecules and adaptor proteins to mediate specific cellular responses.